In This Article:
According to a Reuters report, a U.S. appeals court has reopened a lawsuit brought by the conservative group in Do No Harm, challenging Pfizer's fellowship program meant to provide Black, Latino, and Native American people leadership chances.Reversing their 2022 decision, which concluded Do No Harm had standing to sue, the 2nd U.S. Circuit Court of Appeals in New York That ruling mandated groups to name particular members injured by claimed discrimination, a criteria critics claimed may deter civil rights complaints by subjecting people to possible harassment.
The court decided the lower court should review the matter since it used an overly rigorous criteria. Pfizer defended the initiative, saying lower court processes would handle the accusations and they lacked validity. Representing medical professionals, Do No Harm contends the fellowship rejects applicants from white and Asian-American backgrounds.Following the U.S. Supreme Court's 2023 ruling rejecting race-conscious college admissions methods, this complaint fits a larger wave of legal challenges to diversity programs.
This article first appeared on GuruFocus.